Raymond James Financial’s iRadimed IRMD Stock Holding History

Raymond James Financial’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Sell	13,568 -20,180	-60%	-$2.02M	﹤0.01%	3680
2025 Q4	$3.29M	Sell	33,748 -7,794	-19%	-$669K	﹤0.01%	2852
2025 Q3	$2.96M	Sell	41,542 -1,410	-3%	-$93.9K	﹤0.01%	2874
2025 Q2	$2.57M	Buy	42,952 +1,918	+5%	+$105K	﹤0.01%	2871
2025 Q1	$2.15M	Sell	41,034 -1,136	-3%	-$63.8K	﹤0.01%	2929
2024 Q4	$2.32M	Buy	+42,170	New	+$2.22M	﹤0.01%	2858

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's IRMD Position: Q1 2026 in Review

Raymond James Financial reduced its iRadimed (IRMD) stake by 60% in Q1 2026, selling an estimated $2.02M and leaving 13,568 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Raymond James Financial first reported a position in IRMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.29M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Raymond James Financial held 13,568 shares of iRadimed worth $1.29M as of Q1 2026.
Raymond James Financial sold 20,180 iRadimed shares in Q1 2026, an estimated $2.02M.
iRadimed made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3680 holding.
Raymond James Financial first reported a position in iRadimed in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's iRadimed position peaked at $3.29M in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.